enokizumab (MEDI-528) / AstraZeneca, Ligand - LARVOL DELTA

Mapping knowledge structure and research of the biologic treatment of asthma: A bibliometric study. (PubMed, Front Immunol) - "The search strategies were as follows: topic: TS=(biologic* OR "biologic* product*" OR "biologic* therap*" OR biotherapy* OR "biologic* agent*" OR Benralizumab OR "MEDI-563" OR Fasenra OR "BIW-8405" OR Dupilumab OR SAR231893 OR "SAR-231893" OR Dupixent OR REGN668 OR "REGN-668" OR Mepolizumab OR Bosatria OR "SB-240563" OR SB240563 OR Nucala OR Omalizumab OR Xolair OR Reslizumab OR "SCH-55700" OR SCH55700 OR "CEP-38072" OR CEP38072 OR Cinqair OR "DCP-835" OR DCP835 OR Tezspire OR "tezepelumab-ekko" OR "AMG-157" OR tezspire OR "MEDI-9929" OR "MEDI-19929" OR MEDI9929 OR Itepekimab OR "REGN-3500"OR REGN3500 OR "SAR-440340"OR SAR440340 OR Tralokinumab OR "CAT-354" OR Anrukinzumab OR "IMA-638" OR Lebrikizumab OR "RO-5490255"OR "RG-3637"OR "TNX-650"OR..."

Journal • Asthma • Cough • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

A phase 2b, randomized study to evaluate the clinical activity and safety profile of subcutaneous MEDI-528, an anti-IL-9 monoclonal antibody, in adults with uncontrolled asthma (ATS 2012) - P2, N=327; Adding MEDI-528 to existing controller medications was not associated with any major safety signals or improvement in ACQ-6 score, lung function, or rate of asthma exacerbation

P2 data • Immunology

Development pipeline (AstraZeneca) - Discontinued in asthma for safety / efficacy

Discontinued • Immunology

A phase 2A study to evaluate the safety and effect on exercise challenge testing of MEDI-528 in adults with asthma (clinicaltrials.gov) - P2, N=11; N: 54->11; Completion date: Jun '06->Oct '06

Completion date • Enrollment • Asthma